Australia markets close in 2 hours 56 minutes

Oculis Holding AG (OCS)

NasdaqGM - NasdaqGM Delayed price. Currency in USD
Add to watchlist
12.54-0.01 (-0.08%)
At close: 02:52PM EST
Full screen
Trade prices are not sourced from all markets
Previous close12.55
Open12.60
Bid12.50 x 1100
Ask14.50 x 1800
Day's range12.54 - 12.60
52-week range6.26 - 14.50
Volume560
Avg. volume40,628
Market cap456.9M
Beta (5Y monthly)0.23
PE ratio (TTM)N/A
EPS (TTM)-2.66
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est32.23
  • GlobeNewswire

    Oculis to Present at Upcoming February Investor Conferences

    ZUG, Switzerland and BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis’ management will be attending and presenting at the following upcoming investor conferences: Stifel Biotech Executive Summit Format: Fireside chat Presenter: Riad Sherif, MD, Chief Executive OfficerPresentation date and time: February 7, 2024 at 7:30 am MT (Mountain Time)Lo

  • GlobeNewswire

    Oculis to Host In-Person & Virtual R&D Day in New York on February 28, 2024

    ZUG, Switzerland, and BOSTON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis” or “the Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced it will host an in-person R&D Day in Midtown, New York City, on Wednesday, February 28, 2024 from 9:00 AM to 11:00 AM ET. Please click here to attend the event either in-person or virtually. Location details for in-person attendance will be provided upon registration.

  • GlobeNewswire

    Oculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery

    Initiation of the second Phase 3 OPTIMIZE-2 trial with OCS-01 once daily eye drop, follows the recently reported positive OPTIMIZE-1 trial results OPTIMIZE-2 topline readout expected before end of 2024 to support NDA submissionOCS-01 is also being evaluated as potentially the first topical eye drop treatment for Diabetic Macular Edema (DME) in the DIAMOND program and for the treatment of Cystoid Macular Edema (CME) in the LEOPARD trial ZUG, Switzerland, and BOSTON, Dec. 20, 2023 (GLOBE NEWSWIRE)